$8.19
-0.97%BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Chairperson & Chief Executive Officer
Chief Financial Officer
Chief Legal Officer
During the last 12 months, insiders have purchased $40.50M and sold $420K worth of BBOT shares, resulting in $40.08M of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
1.6M
20.08M
0
0.00
+20.1M
+$20.08M
2.1M
20.42M
81.1K
419.94K
+20.0M
+$20.00M
Wallace Eli M.
Director, Officer: Chief Executive Officer
$24.88M
Mehra Uneek
Officer: Chief Financial Officer
$6.08M
Beltran Pedro
Officer: Chief Scientific Officer
$3.43M
Ben Yong
Officer: Chief Med & Dev Officer
$3.43M
Bauer Jake
Director
$1.33M
Tipirneni Praveen P.
Director
$420K
Strong bullish signal with $40.08M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
BBOT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 16, 2026 | 2026 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.